How to reconstitute retatrutide
To reconstitute retatrutide, a measured amount of bacteriostatic water is added to the powder vial, and the vial is rolled gently until the liquid is clear. The amount of water sets the concentration, which sets how many syringe units hold a given amount. There is no official mixing instruction, because retatrutide is not an approved product.1
Important. The FDA says retatrutide is not part of any FDA-approved product, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. It urges people not to buy products sold "for research purposes", because their quality is unknown and they may be harmful.1 This page explains technique and arithmetic. It does not recommend using retatrutide or any dose of it.
Retatrutide reconstitution calculator
Result
- Volume
- Concentration
- Doses per vial
How this was worked out
The same dose with other amounts of water
| Water | mg/mL | Units |
|---|
Arithmetic for comparison only, not a suggestion to change your mix. More water means more units for the same dose.
This is arithmetic on the numbers you entered. It does not tell you what dose to take. Confirm with your prescriber or pharmacist.
Want to save this vial and get dose reminders? Get early access
Retatrutide at a glance
- What it is: one molecule that activates three hormone receptors: GIP, GLP-1 and glucagon.7
- Developer: Eli Lilly.7
- FDA status: not part of any approved product.1
- Legal supply: only to people in Lilly's clinical trials.9
- How trials gave it: once a week.7
- Doses in Phase 3: 4 mg, 9 mg and 12 mg, each reached in steps from 2 mg.9, 7
- Compounding: not permitted under US federal law.1
- Official mixing instructions: none. There is no approved label.1
- Next step: Lilly plans to submit to the FDA in the first quarter of 2027.7
What you need
A hospital guide for patients who mix an injectable medicine at home lists these supplies:2
- The vial of powder
- The vial of liquid
- A new syringe and needle
- Alcohol pads
- A sharps container
For the liquid, see what bacteriostatic water is.
Before you start
- Know your numbers: the amount on the vial label (mg) and the amount of water you will add (mL).
- There are no maker's instructions to follow. Lilly, the company developing retatrutide, calls it investigational and says it cannot legally be sold or marketed for human use.7 It follows that a vial sold online has no approved label behind it.1
- Check the water. The label for bacteriostatic water says not to use it unless the solution is clear and the seal is intact.6
How to reconstitute retatrutide, step by step
These steps are the general technique for mixing a powder vial. They come from a hospital guide for patients and from one manufacturer's instructions for a different medicine. Neither was written for retatrutide.
- Wash your hands with soap and water for 20 seconds, or use an alcohol hand sanitizer.2
- Flip the caps off both vials without touching the rubber stoppers.2
- Wipe each stopper with an alcohol pad and let it air dry. Do not blow on it.2, 4
- Pull air into the syringe equal to the amount of water you will draw, then push that air into the water vial.2
- Draw the water. Turn the vial upside down, keep the needle tip under the liquid, and pull back to your amount. If the needle touches anything but the cleaned stopper, throw it away and start over.2
- Add the water to the powder slowly. One manufacturer's instructions say the liquid should run down the inside wall of the vial and not fall straight onto the powder.3
- Take the needle out and put it in the sharps container.2 Never leave a needle in a vial.4, 5
- Roll, do not shake. Roll the vial gently between your palms until the powder dissolves. Shaking can damage the medicine.2, 3
- Check that it is clear. The same instructions say not to use a vial that is cloudy, coloured, foamy or has particles in it.3
- Write the date and time on the vial.2
For more detail on each step, see how to reconstitute peptides.
How much BAC water for each vial size
There is no official amount of water for any retatrutide vial, because there is no approved product.1 What can be stated is the arithmetic. The water you add does not change how much retatrutide is in the vial. It changes the concentration:
concentration (mg/mL) = amount in vial (mg) ÷ water added (mL)
| Vial | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 |
| 12 mg | 12 | 6 | 4 |
| 15 mg | 15 | 7.5 | 5 |
| 20 mg | 20 | 10 | 6.67 |
| 30 mg | 30 | 15 | 10 |
See how much BAC water to add for what a stronger or weaker mix changes in practice.
Turning milligrams into syringe units
On a U-100 insulin syringe, 100 units equal 1 mL.8 So the number of units for 1 mg depends on the concentration:
units for 1 mg = 1 ÷ concentration (mg/mL) × 100
| Vial | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 5 mg | 20 | 40 | 60 |
| 10 mg | 10 | 20 | 30 |
| 12 mg | 8.3 | 16.7 | 25 |
| 15 mg | 6.7 | 13.3 | 20 |
| 20 mg | 5 | 10 | 15 |
| 30 mg | 3.3 | 6.7 | 10 |
For example, by arithmetic, a 10 mg vial with 2 mL of water is 5 mg/mL, so 1 mg is 20 units. That is an illustration, not a recommendation. Each vial size also has its own page: 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 30 mg.
Retatrutide dosing: what the trials used
People often look for a dose to go with the mixing math. Retatrutide has no label, so the only doses with data behind them are the ones in Lilly's trials. They are reported here as trial facts, not as advice.
Phase 2 trial (2023)
The Phase 2 trial gave 338 adults with obesity, or overweight with a weight-related condition, retatrutide or a placebo under the skin once a week for 48 weeks. None had type 2 diabetes. Some groups started at 2 mg and some at 4 mg.10
| Dose | Start | 24 wk | 48 wk |
|---|---|---|---|
| 1 mg | 1 | -7.2 | -8.7 |
| 4 mg | 2 or 4 | -12.9 | -17.1 |
| 8 mg | 2 or 4 | -17.3 | -22.8 |
| 12 mg | 2 | -17.5 | -24.2 |
| Placebo | -1.6 | -2.1 |
Sources for the table: the dose groups and starting doses are from Lilly's release, and the figures for each group are from a medical news report of the paper.10, 11 Lilly's release gives the top results as up to 17.5% at 24 weeks and up to 24.2% at 48 weeks, which match.10 We could not open the journal paper itself.
Side effects in Phase 2 were mostly stomach and bowel related, generally mild to moderate, and usually came while the dose was being stepped up.10 The news report adds that most were dose-related and were partly eased by a lower starting dose.11
How the Phase 3 doses were reached
In the Phase 3 TRIUMPH trials, retatrutide was given once a week. Everyone started at 2 mg and the dose went up every four weeks until it reached the target for that group.9, 7
| Target dose | Steps on the way |
|---|---|
| 4 mg | 2 mg |
| 9 mg | 2, 4, 6 mg |
| 12 mg | 2, 4, 6, 9 mg |
Source for the table: Lilly's TRIUMPH-1 release.9
What the Phase 3 trials found
All three trials ran for 80 weeks and compared retatrutide with a placebo. The figures are average change in body weight, as reported by the company. Lilly's releases say detailed results will be published in peer-reviewed journals later.9, 7
| Dose | T-1 | T-2 | T-3 |
|---|---|---|---|
| 4 mg | -19.0 | -12.7 | † |
| 9 mg | -25.9 | -19.1 | -21.6 |
| 12 mg | -28.3 | -20.8 | -22.6 |
| Placebo | -2.2 | -4.0 | -3.2 |
- TRIUMPH-1: 2,339 adults with obesity or overweight and a weight-related condition, without diabetes.9
- TRIUMPH-2: 1,152 adults with type 2 diabetes and obesity or overweight.7
- TRIUMPH-3: 1,949 adults with severe obesity and established cardiovascular disease.7
For more on these trials, see retatrutide dosage: what the trials tested.
Why a trial dose is not a protocol
Trial participants were given the company's own product, and Lilly says retatrutide is legally available only to people in its trials.9 A vial bought online is a different thing: the FDA says the quality of such products is unknown.1 The company's releases also do not say how the trial medicine was supplied, so they give no mixing instructions.7 How much anyone should take is a decision for a licensed prescriber, and today no approved retatrutide product exists to prescribe.1
Side effects reported in the trials
Stomach and bowel effects were the most common, and most were more frequent at higher doses.9, 7
In TRIUMPH-1, these shares of participants reported each event:9
- Nausea: 28.6% on 4 mg, 38.4% on 9 mg, 42.4% on 12 mg, and 14.8% on placebo.
- Diarrhea: 25.2%, 34.1% and 32.0%, against 13.5% on placebo.
- Constipation: 23.8%, 25.9% and 26.1%, against 10.9% on placebo.
- Vomiting: 10.6%, 22.8% and 25.3%, against 4.8% on placebo.
- Dysesthesia: 5.1%, 12.3% and 12.5%, against 0.9% on placebo.
Dysesthesia means an abnormal, unpleasant skin sensation. Lilly reported that these events were generally mild to moderate and that most resolved during treatment.9
| Dose | T-1 | T-2 | T-3 |
|---|---|---|---|
| 4 mg | 4.1% | 3.8% | † |
| 9 mg | 6.9% | 11.6% | 9.8% |
| 12 mg | 11.3% | 7.7% | 13.5% |
| Placebo | 4.9% | 4.9% | 4.8% |
Source for the table: Lilly's releases.9, 7 These numbers describe people taking the trial product under supervision. They say nothing about the contents or safety of a vial sold online.1
Where approval stands
- Not approved. The FDA says retatrutide is not part of any approved product and has not been found safe and effective for any condition.1
- Not available through compounding. The FDA says it cannot be used in compounding under federal law, and it has sent warning letters to telehealth companies marketing it.1
- "Research use" products. The FDA has warned companies that sold retatrutide labelled "for research purposes" or "not for human consumption" directly to consumers, and urges people not to buy them.1
- Submission planned. Lilly says it is finishing its manufacturing data and plans to submit retatrutide for US approval in the first quarter of 2027.7
- More trials are running. Lilly lists Phase 3 trials in type 2 diabetes, knee osteoarthritis pain, sleep apnea, chronic low back pain, heart and kidney outcomes, and a form of fatty liver disease.7
Keep a record of every vial
Three numbers decide every measurement from a mixed vial: the amount on the label, the water added, and the date it was mixed. Write all three on the vial. If any one is forgotten, the concentration can no longer be worked out. Bring the same record to any conversation with a clinician.
How long does mixed retatrutide last?
There is no tested answer. A storage time comes from the label of an approved product, and retatrutide has none.1 Here is what the sources we read do say:
- The water's own label says not to store mixed solutions unless the maker of the drug directs otherwise.6
- The "28 days" seen online matches a rule for healthcare settings: the CDC says an opened multi-dose vial should be dated and thrown away within 28 days unless the manufacturer states another date.5 That rule is about infection control for multi-dose vials in general. Linking it to the 28 days quoted for retatrutide is our inference, and it is not a tested shelf life for mixed retatrutide.
- Real limits can be far shorter. One approved medicine that is mixed from powder must be injected within 6 hours of mixing.3
We do not give a number of days, because no source sets one for retatrutide. For the water itself, see how to store BAC water.
Common mistakes
- Shaking the vial. Roll it instead.2, 3
- Reusing a syringe. Health guidance says not to reuse a syringe even if the needle is changed.4
- Leaving a needle in the stopper. It gives germs a direct route into the vial.5
- Skipping the stopper wipe on later draws. Wipe it with alcohol and let it dry before every entry.4
- Forgetting how much water went in. Without that number the concentration is unknown, and so is every dose drawn from the vial. Write it on the vial with the date.
- Treating units as milligrams. See units are not milligrams.
Measuring errors do real harm. The FDA has received reports of adverse events, some needing hospital care, that may be related to dosing errors with compounded injectable semaglutide, including patients measuring and injecting the wrong amount.1
Questions
How do you reconstitute retatrutide?
In outline: clean your hands and both vial stoppers, draw up a measured amount of bacteriostatic water, add it slowly down the inside wall of the powder vial, roll the vial gently until the powder dissolves, check the liquid is clear, and write the date on the vial. No official instruction exists, because retatrutide is not an approved product.
How much BAC water do you add to 10 mg of retatrutide?
There is no official amount. By arithmetic, 1 mL makes 10 mg/mL, 2 mL makes 5 mg/mL and 3 mL makes 3.33 mg/mL. The amount of water changes the concentration, not how much retatrutide is in the vial.
How much BAC water for a 30 mg retatrutide vial?
There is no official amount. By arithmetic, 1 mL makes 30 mg/mL, 2 mL makes 15 mg/mL and 3 mL makes 10 mg/mL.
How many units is 1 mg of retatrutide?
It depends on the mix. For a 10 mg vial with 2 mL of water, 1 mg is 20 units on a U-100 insulin syringe. With a different vial size or amount of water the number changes, so use the calculator with your own numbers.
How many mg is 20 units of retatrutide?
It depends on the mix. For a 10 mg vial with 2 mL of water, 20 units hold 1 mg. A different vial size or amount of water gives a different answer.
How much BAC water for a 20 mg retatrutide vial?
There is no official amount. By arithmetic, 1 mL makes 20 mg/mL, 2 mL makes 10 mg/mL and 3 mL makes 6.67 mg/mL.
What doses of retatrutide did the trials use?
The Phase 3 TRIUMPH trials tested 4 mg, 9 mg and 12 mg once a week. Every participant started at 2 mg a week and moved up every four weeks. The earlier Phase 2 trial tested 1 mg, 4 mg, 8 mg and 12 mg once a week. Those are trial facts, not advice.
Is there a beginner dosage chart for retatrutide?
Not an official one. Retatrutide has no approved label, so no dosage chart exists. The charts on this page convert amounts to concentration and syringe units. They do not say what amount to use.
What are the most common side effects of retatrutide?
In the Phase 3 trials the most common were nausea, diarrhea, constipation and vomiting, and they were more frequent at higher doses. Lilly also reported dysesthesia, an abnormal skin sensation, in up to about 1 in 8 participants on the higher doses in one trial.
Can a pharmacy compound retatrutide?
No. The FDA says retatrutide cannot be used in compounding under federal law.
When could retatrutide be approved?
Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. An approval date is not known.
How long does reconstituted retatrutide last?
No one can give a tested answer, because retatrutide has no approved label and so no official storage instructions. The 28 days often quoted online matches a healthcare rule for opened multi-dose vials in general. It is not a tested shelf life for mixed retatrutide.
Should you shake retatrutide after adding water?
No. The hospital guide and the manufacturer instructions we read for other injectable medicines both say to roll the vial gently, because shaking can damage the medicine.
What if the mixed vial looks cloudy?
Do not use it. The manufacturer instructions we read for another injectable medicine say not to use a vial that is cloudy, coloured, foamy or has particles in it.
Can you use sterile water instead of bacteriostatic water?
We found no official instruction for retatrutide either way, because no approved product exists. Bacteriostatic water contains a preservative and plain sterile water does not. Ask a pharmacist before changing the liquid.
Is retatrutide FDA-approved?
No. The FDA says retatrutide is not part of any approved product, has not been found safe and effective for any condition, and cannot be used in compounding.
Does this guide tell me what dose to take?
No. It covers mixing and the arithmetic. It does not suggest a dose.
Sources
- U.S. Food and Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss", content current as of 1 October 2026. fda.gov (opens in a new tab)
- St. Jude Children's Research Hospital, "Making liquid medicine for injection", patient education guide. together.stjude.org (opens in a new tab)
- Pfizer, Somavert (pegvisomant) Instructions for Use, revised July 2023. Used here as an example of a manufacturer's mixing instructions. pfizermedicalinformation.com (opens in a new tab)
- World Health Organization, "WHO Best Practices for Injections and Related Procedures Toolkit", chapter 2, 2010. Written for healthcare settings. ncbi.nlm.nih.gov (opens in a new tab)
- Centers for Disease Control and Prevention, "Preventing Unsafe Injection Practices", 26 March 2024. Written for healthcare settings. cdc.gov (opens in a new tab)
- Hospira, Inc., Bacteriostatic Water for Injection, USP, prescribing information, revised 11/2019. labeling.pfizer.com (opens in a new tab)
- Eli Lilly and Company, press release, 23 July 2026: topline results from TRIUMPH-2 and TRIUMPH-3. Company release, not peer-reviewed. investor.lilly.com (opens in a new tab)
- Pennsylvania Patient Safety Authority, newsletter, June 2025: insulin syringes are marked in units, with 1 mL equal to 100 units. patientsafety.pa.gov (opens in a new tab)
- Eli Lilly and Company, press release, 21 May 2026: topline results from TRIUMPH-1 (NCT05929066). Company release, not peer-reviewed. investor.lilly.com (opens in a new tab)
- Eli Lilly and Company, press release, 26 June 2023: Phase 2 retatrutide results published in the New England Journal of Medicine (NCT04881760). Company release. investor.lilly.com (opens in a new tab)
- Campbell P. "Retatrutide Showcases Weight-Lowering, Glycemic Control Benefits in Phase 2 Data." HCPLive, 26 June 2023. A medical news report of the Phase 2 paper (Jastreboff AM, et al., New England Journal of Medicine, 2023), which we could not open ourselves. hcplive.com (opens in a new tab)
- Formulas and test cases: how the calculator math works.